Содержание
Перейти к:
Инсулинотерапия и масса тела. Преимущества применения двухфазного аналога инсулина НовоМикс 30
https://doi.org/10.14341/2072-0351-3597
Аннотация
Для цитирования:
Суркова Е.В. Инсулинотерапия и масса тела. Преимущества применения двухфазного аналога инсулина НовоМикс 30. Сахарный диабет. 2013;16(1):52-56. https://doi.org/10.14341/2072-0351-3597
For citation:
Surkova E.V. Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30. Diabetes mellitus. 2013;16(1):52-56. (In Russ.) https://doi.org/10.14341/2072-0351-3597
Список литературы
1. Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effect of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab. 2001 Dec;3(6):410–416.
2. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group Diabetes Care. 1988 Jul–Aug;11(7):567–573.
3. Strachan MW, Ewing FM, Frier BM, Harper A, Deary IJ. Food craving during acute hypoglycaemia in adults with type 1 dia- betes. Physiol Behav. 2004 Feb;80(5):675–682.
4. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep. 2001 Apr;2(4):282–286.
5. Hollander P. Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes. Diabetes spectrum. 2007;20(3):159–165. DOI: 10.2337/di- aspect.20.3.159
6. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000 Apr 6;404(6778):661–671.
7. Ryan M, Livingstone MB, Ducluzeau PH, Sallé A, Genaitay M, Ritz P. Is a failure to recognize an increase in food intake a key to understanding insulin-induced weight gain? Diabetes Care. 2008 Mar;31(3):448–450.
8. Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes. Diabetes Care. 2001 Oct;24(10):1849–1850.
9. American Diabetes Association. Shaban J, Hansen JB, Wenying Y. NovoMix 30 (BIAsp 30) Improves Glycemic Control in Type 2 Diabetes: Results from the IMPROVE Study. Diabetes Care. 2008 Jan;31 Suppl 1:S12–54. DOI: 10.2337/dc08-S012.
10. Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM; PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008 Mar;10(3):212–222. DOI: 10.1111/j.1463–1326.2007.00826.x.
11. Shestakova M, Sharma SK, Almustafa M, Min KW, Ayad N, Azar ST, Danciulescu R, Khutsoane D, Guler S. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007 Dec;23(12):3209–3214.
12. Valency P. Biphasic insulin aspart 30/70 (BiAsp 30) in the treatment of type 1 and type 2 diabetes. Diabetes Metab Syndr Obes. 2009 Jun 3;2:61–71.
13. Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M. Starting Insulin Therapy in Type 2 Diabetes: Twice-Daily Biphasic Insulin Aspart 30 Plus Metformin versus Once-Daily Insulin Glargine Plus Glimepiride. Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):527–532.
14. Ligthelm RJ. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice. Prim Care Diabetes. 2009 May;3(2):97–102. DOI: 10.1016/j.pcd.2009.01.003.
15. Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J Endocrinol Invest. 2009 Jan;32(1):23–27.
16. Arai K, Hirao K, Yamauchi M, Takagi H, Kobayashi M; Japan Diabetes Clinical Data Management Study Group. Influence of BMI, Age and Duration of Diabetes Mellitus on Glycaemic Control with Twice-Daily Injections of Biphasic Insulin Aspart 30 versus Multiple Daily Injections of Insulin Aspart (JDDM 18) Retrospective Reanalysis of a 6-Month, Randomized, Open-Label, Multicentre Trial in Japan. Clin Drug Investig. 2010;30(1):35–40.DOI: 10.2165/11530920-000000000-00000.
17. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):148–152. DOI: 10.1097/ MED.0b013e3283444ba0.
18. Tilling LM, Darawill K, Britton M. Falls as a complication of diabetes mellitus in older people. J Diabetes Complications. 2006 May–Jun;20(3):158–162.
19. Jang HC, Lee SR, Vaz JA. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMix study. Diabetes Obes Metab. 2009 Jan;11(1):20–26. DOI: 10.1111/j.1463- 1326.2008.00891.x.
20. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams- Huet B, Raskin P. Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2. Diabetes Care. 2009 Oct;32(10):1789–1795. DOI: 10.2337/dc09-0653.
21. Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int J Clin Pract. 2011 Feb;65(2):165–171. DOI: 10.1111/j.1742-1241.2010.02513.x.
Рецензия
Для цитирования:
Суркова Е.В. Инсулинотерапия и масса тела. Преимущества применения двухфазного аналога инсулина НовоМикс 30. Сахарный диабет. 2013;16(1):52-56. https://doi.org/10.14341/2072-0351-3597
For citation:
Surkova E.V. Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30. Diabetes mellitus. 2013;16(1):52-56. (In Russ.) https://doi.org/10.14341/2072-0351-3597
Просмотров: 994
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Послать статью по эл. почте 
